The results of this primary analysis of two doses of chadox1 ncov 19 were consistent with those seen in the interim analysis of the trials and confirm that the vaccine is efficacious with results varying by dose interval in exploratory analyses a 3 month dose interval might have advantages over a programme with a short dose interval for roll out of a pandemic hellip.